ANDEMBRY®, the first and only once-monthly treatment targeting factor XIIa to prevent attacks in HAE patients, inhibits ...
Featuring releases from CSL, CSL Behring, CSL Seqirus and CSL Vifor.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback